CN102727509A - Application of baicalin to preparation of medicament for treating pneumonia - Google Patents
Application of baicalin to preparation of medicament for treating pneumonia Download PDFInfo
- Publication number
- CN102727509A CN102727509A CN2011100919898A CN201110091989A CN102727509A CN 102727509 A CN102727509 A CN 102727509A CN 2011100919898 A CN2011100919898 A CN 2011100919898A CN 201110091989 A CN201110091989 A CN 201110091989A CN 102727509 A CN102727509 A CN 102727509A
- Authority
- CN
- China
- Prior art keywords
- baicalin
- pneumonia
- application
- medicament
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to application of baicalin to preparation of a medicament for treating pneumonia. A rabbit erythrocyte hemolysis test, a human pulmonary epithelial cell (A549) injury protection test and a mouse Staphylococcus aureus pneumonia model are employed to confirm the treatment effect of the baicalin. Compared with an antibiotic therapy, the use of baicalin has characteristics of no drug resistance and high cure rate.
Description
Technical field
The present invention relates to the application of baicalin in preparation treatment pneumonia medicine, belong to field of medicaments.
One, background technology
Baicalin (Baicalin) is a kind of flavone compound that extraction separation comes out from scutellariae,radix, has tangible antifungal activity, and especially to yeast type fungus tool selectively acting, minimum inhibitory concentration (MIC) is between 70-100 μ g/ml.But do not see that baicalin is used to treat cellularity pneumonia report.
Bacterial pneumonia is that institutes such as pneumonia infection diplococcus, staphylococcus, streptococcus, hemophilus influenza, pneumobacillus cause.Bacterial pneumonia accounts for 80% of all kinds of pathogen pneumonia of adult.Because of much more serious the pneumonia state of an illness due to the staphy lococcus infection is, present therapeutic scheme uses oxazacillin (benzylpencilline) and cloxacillin (cloxacillin) usually, alternative the 1st generation, the 2nd generation cephalosporin.But use the maximum shortcoming of antibiotic therapy to be to be prone to produce drug resistance, can make the treatment failure.Therefore need to seek to have no drug resistance and safe and reliable medicine.Baicalin derives from Chinese medicine, and the present invention studies and confirms it to bacterial pneumonia, and especially golden Portugal bacterium pneumonia infection has actively useful effect.
Two, summary of the invention
The molecular structure of baicalin is following:
It treats golden Portugal bacterium infection effect protection test and the mice gold Portugal bacterium pneumonia model validation of the present invention through the damage of rabbit erythrocyte hemolytic test, people's pulmonary epithelial cells (A549).
Three, the specific embodiment
1. hemolytic test
The alpha hemolysin of purification is done successive doubling dilution in 96 orifice plates, add 10 in each hole
7Individual rabbit erythrocyte, centrifugal after in 37 ℃, hatching 30h.Make haemoclastic highly diluted multiple be regarded as haemolysis titre (Hemolysis titre).The haemolysis titre such as the following table 1 that do not add alpha hemolysin behind baicalin and the baicalin that adds variable concentrations:
Table 1. baicalin is to the inhibitory action of alpha hemolysin hemolytic activity
| Baicalin (μ g/ml) | Haemolysis titre (Hemolysis titre) |
| 0 | 2048 |
| 16 | 32 |
| 8 | 128 |
| 4 | 256 |
| 2 | 1024 |
2. the protection test of people's pulmonary epithelial cells (A549) damage
The gold bacterium 8325-4 of Portugal is cultured to OD in the TSB culture medium
600nm=0.5, get the bacterial cultures of 5ml, centrifugal and be resuspended in the F12K culture medium of 10ml.The A549 cell in F12K culture medium (adding 10% hyclone) in 37 ℃, 5%CO
2Cultivate after 24 hours, with 1.5 * 10
4Individual cells/well is laid in the 96 porocyte culture plates, every hole 100 μ l.Behind the cell attachment, add 100 μ l gold Portugal bacteria suspension, and add the baicalin of variable concentrations, place cell culture incubator in 37 ℃, 5%CO
2Cultivate 8h altogether.Add live (green)/dead (red) reagent, the state of A549 cell is observed in the back under laser confocal microscope (LSCM), and it is green that living cells shows, and dead cell shows redness.
The result shows, people's pulmonary epithelial cells (A549) damage that baicalin can the bacterium alpha hemolysin mediation of protective money Portugal, and this effect presents dose dependent.
3. the experimental therapeutic research of mice gold Portugal bacterium pneumonia
3.1 mice gold Portugal bacterium pneumonia model
(male, 18-22g) behind etherization, per nasal gives 30 μ l gold Portugal's bacteria suspension (the golden bacterium 8325-4 of Portugal) to the C57BL/6J mice, and mice lies low until reviving, and sets up the model of mice gold Portugal bacterium pneumonia.The test that causes death is given with 4 * 10
8The golden Portugal bacterium of CFUs, and histopathology is investigated to 2 * 10
8The golden Portugal bacterium of CFUs.
3.2 protective rate test
The baicalin of 2h difference subcutaneous injection 100,50 and 25mg/kg (100 μ l) behind the mouse inoculation gold Portugal bacterium, every 6h is administered once.Not administration matched group is given the normal saline with 100 μ l, every group of 30 mices.By after the dosage regimen administration, write down the mouse infection gold bacterium 24h of Portugal respectively, 48h, the mortality rate behind the 72h.
The result shows, after baicalin is handled, significantly reduces the mortality rate (P＜0.05) of mice gold Portugal bacterium pneumonia.Like table 2.
Table 2. baicalin is to the influence of mice gold Portugal bacterium pneumonia mortality rate
Claims (4)
1. the application of baicalin in preparation treatment pneumonia medicine.
2. medicine comprises pharmaceutically acceptable dosage form according to claim 1.
3. pneumonia refers to bacterial pneumonia and fungal pneumonia according to claim 1.
4. be meant the pneumonia that causes by staphylococcus aureus like the said bacterial pneumonia of claim 3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100919898A CN102727509A (en) | 2011-04-13 | 2011-04-13 | Application of baicalin to preparation of medicament for treating pneumonia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100919898A CN102727509A (en) | 2011-04-13 | 2011-04-13 | Application of baicalin to preparation of medicament for treating pneumonia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102727509A true CN102727509A (en) | 2012-10-17 |
Family
ID=46984277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100919898A Pending CN102727509A (en) | 2011-04-13 | 2011-04-13 | Application of baicalin to preparation of medicament for treating pneumonia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102727509A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103479659A (en) * | 2013-10-16 | 2014-01-01 | 吉林大学 | Application of three kinds of oroxin in preparing drug for resisting staphylococcus aureus infection |
| CN106474141A (en) * | 2016-10-13 | 2017-03-08 | 吉林大学 | Osthole is combined application in preparation treatment pneumonia medicine for the baicalin |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101176722A (en) * | 2006-11-12 | 2008-05-14 | 黑龙江大学 | Scutellaria glycosides freeze dried injection solution and preparation method thereof |
-
2011
- 2011-04-13 CN CN2011100919898A patent/CN102727509A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101176722A (en) * | 2006-11-12 | 2008-05-14 | 黑龙江大学 | Scutellaria glycosides freeze dried injection solution and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 文敏等: "黄芩苷药理作用研究新进展", 《沈阳药科大学学报》 * |
| 邝枣园等: "黄芩苷抗肺炎衣原体的研究", 《中国微生态学杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103479659A (en) * | 2013-10-16 | 2014-01-01 | 吉林大学 | Application of three kinds of oroxin in preparing drug for resisting staphylococcus aureus infection |
| CN106474141A (en) * | 2016-10-13 | 2017-03-08 | 吉林大学 | Osthole is combined application in preparation treatment pneumonia medicine for the baicalin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107308288B (en) | A Chinese medicinal shampoo for preventing and treating alopecia and scalp pruritus | |
| CN102727509A (en) | Application of baicalin to preparation of medicament for treating pneumonia | |
| CN103191100A (en) | Application of puerarin in preparation of drug for treating pneumonia | |
| CN102872004B (en) | Application of the naringenin in treatment pneumonia medicine is prepared | |
| CN105412131A (en) | Application of verbascoside in preparation of pneumonia treatment drug | |
| CN102429899A (en) | Application of baicalein to preparation of medicament for treating pneumonia | |
| CN102755311A (en) | Application of oroxylin A in preparing medicament for treating pneumonia | |
| CN102872003B (en) | Application of the apiolin in treatment pneumonia medicine is prepared | |
| CN102872005B (en) | Application of the glycyrrhizin in treatment pneumonia medicine is prepared | |
| CN106474141A (en) | Osthole is combined application in preparation treatment pneumonia medicine for the baicalin | |
| CN115300521A (en) | Application of narirutin in preparation of Sortase A sortase and PLY hemolysin inhibitor | |
| CN106668100B (en) | Application of Babaodan in preparing medicament for treating meningitis | |
| CN107714678A (en) | Application of the pterostilbene in the enzyme inhibitors of MCR 1 are prepared | |
| CN105193784B (en) | Application of the ginkgetin in preparation treatment streptococcus suis infection drug | |
| CN109464439A (en) | Osthole is preparing the application in MCR-1 enzyme inhibitor | |
| CN105497010A (en) | Application of EGCG in preparing targeted drugs for resisting sepsis bacterial endotoxin | |
| CN111053764B (en) | Application of salvianolic acid A in preparation of medicine for treating methicillin-resistant staphylococcus aureus infectious pneumonia | |
| CN101879174A (en) | Use of forsythiaside A in preparation of drugs for treating influenza | |
| CN102755313A (en) | Application of silibinin in preparation of medicament for treating pneumonia | |
| CN112957354A (en) | Application of parthenolide in preparation of MCR-1 enzyme inhibitor | |
| CN106265630A (en) | Amentoflavone application in research and development treatment pneumonia medicine | |
| CN113440521B (en) | Application of patchoulenone in preparation of MCR-1 enzyme inhibitor | |
| CN106667996B (en) | Morin is preparing the application in anti-streptococcus suis medicine | |
| CN103191099B (en) | The application in anti-listeria infection medicine prepared by fisetin | |
| CN103479659A (en) | Application of three kinds of oroxin in preparing drug for resisting staphylococcus aureus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DD01 | Delivery of document by public notice |
Addressee: Jilin University Deng Xuming Document name: Notification of Passing Preliminary Examination of the Application for Invention |
|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice |
Addressee: Jilin University Document name: Notification of Publication and of Entering the Substantive Examination Stage of the Application for Invention |
|
| DD01 | Delivery of document by public notice |
Addressee: Jilin University Document name: the First Notification of an Office Action |
|
| DD01 | Delivery of document by public notice |
Addressee: Deng Xuming Document name: Notification that Application Deemed to be Withdrawn |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121017 |